| Azacitidine and venetoclax in previously untreated acute myeloid leukemia CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ... New England journal of medicine 383 (7), 617-629, 2020 | 2294 | 2020 |
| The public repository of xenografts enables discovery and randomized phase II-like trials in mice EC Townsend, MA Murakami, A Christodoulou, AL Christie, J Köster, ... Cancer cell 29 (4), 574-586, 2016 | 358 | 2016 |
| Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study J Glasbey, A Ademuyiwa, A Adisa, E AlAmeer, AP Arnaud, F Ayasra, ... The Lancet Oncology 22 (11), 1507-1517, 2021 | 283 | 2021 |
| Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms D Van Egeren, J Escabi, M Nguyen, S Liu, CR Reilly, S Patel, B Kamaz, ... Cell stem cell 28 (3), 514-523. e9, 2021 | 191 | 2021 |
| Delaying surgery for patients with a previous SARS-CoV-2 infection Journal of British Surgery 107 (12), e601-e602, 2020 | 151 | 2020 |
| Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine KW Pratz, BA Jonas, V Pullarkat, C Recher, AC Schuh, MJ Thirman, ... Journal of Clinical Oncology 40 (8), 855-865, 2022 | 135 | 2022 |
| Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia S Bhatt, MS Pioso, EA Olesinski, B Yilma, JA Ryan, T Mashaka, B Leutz, ... Cancer cell 38 (6), 872-890. e6, 2020 | 126 | 2020 |
| Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy CN Harrison, JS Garcia, TCP Somervaille, JM Foran, S Verstovsek, ... Journal of Clinical Oncology 40 (15), 1671-1680, 2022 | 103 | 2022 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ... Anaesthesia 76 (6), 748-758, 2021 | 90 | 2021 |
| Comparative Study of Nasoalveolar Molding Methods: Nasal Elevator plus DynaCleft® Versus NAM-Grayson in Patients with Complete Unilateral Cleft Lip and Palate L Monasterio, A Ford, C Gutiérrez, ME Tastets, J García The Cleft Palate-Craniofacial Journal 50 (5), 548-554, 2013 | 86 | 2013 |
| Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes AM Zeidan, U Platzbecker, JP Bewersdorf, M Stahl, L Adès, U Borate, ... Blood, The Journal of the American Society of Hematology 141 (17), 2047-2061, 2023 | 85 | 2023 |
| Long‐term follow‐up of VIALE‐A: venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia KW Pratz, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, H Döhner, ... American journal of hematology 99 (4), 615-624, 2024 | 81 | 2024 |
| A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies CA Lachowiez, S Loghavi, Z Zeng, T Tanaka, YJ Kim, H Uryu, S Turkalj, ... Blood cancer discovery 4 (4), 276-293, 2023 | 76 | 2023 |
| An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes JS Garcia, N Jain, LA Godley OncoTargets and therapy, 1-13, 2010 | 69 | 2010 |
| Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial NG Daver, M Dail, JS Garcia, BA Jonas, KWL Yee, KR Kelly, N Vey, ... Blood 141 (11), 1265-1276, 2023 | 68 | 2023 |
| Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia M Konopleva, MJ Thirman, KW Pratz, JS Garcia, C Recher, V Pullarkat, ... Clinical Cancer Research 28 (13), 2744-2752, 2022 | 66 | 2022 |
| Outcomes from elective colorectal cancer surgery during the SARS‐CoV‐2 pandemic COVIDSurg Collaborative, JC Glasbey, D Nepogodiev, JFF Simoes, ... Colorectal Disease 23 (3), 732-749, 2021 | 66 | 2021 |
| A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed/refractory myelodysplastic … AM Zeidan, DA Pollyea, JS Garcia, A Brunner, F Roncolato, U Borate, ... Blood 134, 565, 2019 | 66 | 2019 |
| Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase … JS Garcia, AH Wei, U Borate, CY Fong, MR Baer, F Nolte, JG Jurcic, ... Blood 136, 55-57, 2020 | 65 | 2020 |
| SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ... Anaesthesia 77 (1), 28-39, 2022 | 61 | 2022 |
